Trial Profile
A randomized Phase II study of AG-120 in IDH1 mutant positive cholangiocarcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 12 May 2016 New trial record
- 05 May 2016 According to an Agios Pharmaceuticals media release, the company expects to initiate this trial in the second half of 2016.